Clinical Trial Update: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) [Phase 3]

View source ↗

Summary

A Phase 3 trial (MK-3475-585/KEYNOTE-585) evaluating pembrolizumab plus chemotherapy versus chemotherapy alone in gastric cancer and gastroesophageal junction c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Status: COMPLETED | Results posted: 2025-02-20